- Conditions
- Neoplasms
- Interventions
- TSR-033, Dostarlimab, mFOLFOX6, FOLFIRI, Bevacizumab
- Drug
- Lead sponsor
- Tesaro, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 111 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2023
- U.S. locations
- 11
- States / cities
- Los Angeles, California • Whittier, California • Sarasota, Florida + 8 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 769–792
of 1,106
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Advanced Cancer, Metastatic Cancer
- Interventions
- T-DXd
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2028
- U.S. locations
- 2
- States / cities
- Miami, Florida • Durham, North Carolina
- Conditions
- Diabetic Foot Osteomyelitis
- Interventions
- STIMULAN VG, Systemic Antibiotics
- Drug
- Lead sponsor
- Biocomposites Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 61 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 10
- States / cities
- Mesa, Arizona • Phoenix, Arizona • Scottsdale, Arizona + 6 more
- Conditions
- Metastatic Prostate Cancer, Prostate Cancer
- Interventions
- 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-one, FTT-PET/CT, EnhanceAR-Seq
- Drug · Device · Diagnostic Test
- Lead sponsor
- Washington University School of Medicine
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 3
- States / cities
- St Louis, Missouri • Philadelphia, Pennsylvania • Houston, Texas
- Conditions
- Hereditary Cancer Syndrome
- Interventions
- Mainstream Genetic Testing Model, Enhanced Standard of Care Model
- Other
- Lead sponsor
- University of Illinois at Chicago
- Other
- Eligibility
- 25 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Cardiovascular Disease (CVD) Risk Factors
- Interventions
- Modified RICHH, Standard of Care (SOC)
- Behavioral
- Lead sponsor
- Oregon Health and Science University
- Other
- Eligibility
- 21 Years and older
- Enrollment
- 70 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Cardiovascular Disease
- Interventions
- EVARREST™, Topical hemostat, Standard of Care
- Biological · Other
- Lead sponsor
- Ethicon, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 42 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2013
- U.S. locations
- 6
- States / cities
- Indianapolis, Indiana • Kansas City, Missouri • Camden, New Jersey + 2 more
- Conditions
- Pancreatic Cancer
- Interventions
- CPI 613, Oxaliplatin, Irinotecan, 5-flurouracil, Folinic acid
- Drug
- Lead sponsor
- David Bajor, MD
- Other
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 49 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2024
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Triple Negative Breast Cancer
- Interventions
- adagloxad simolenin combined with OBI-821, Globo H IHC Assay, Standard of care treatment
- Biological · Device · Other
- Lead sponsor
- OBI Pharma, Inc
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 575 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2027
- U.S. locations
- 12
- States / cities
- La Jolla, California • San Diego, California • San Francisco, California + 9 more
- Conditions
- Type 2 Diabetes
- Interventions
- phone application, Standard of Care (SOC)
- Device · Other
- Lead sponsor
- University of California, San Francisco
- Other
- Eligibility
- 10 Years to 21 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026
- U.S. locations
- 2
- States / cities
- Oakland, California • San Francisco, California
- Conditions
- Chronic Kidney Disease (Stages 4 and 5), Kidney Disease, Type 2 Diabetes
- Interventions
- Physiologic Insulin Resensitization (PIR)
- Other
- Lead sponsor
- Well Cell Global
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 120 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Phoenix, Arizona • Scottsdale, Arizona
- Conditions
- Upper Resp Tract Infection
- Interventions
- TEM-PCR URI Panel, SOC/Empiric Diagnosis
- Diagnostic Test · Other
- Lead sponsor
- Diatherix Laboratories, LLC
- Industry
- Eligibility
- 65 Years and older
- Enrollment
- 314 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 4
- States / cities
- Athens, Alabama • Huntsville, Alabama
- Conditions
- Cutaneous Malignant Melanoma, Renal Cell Cancer, Urothelial Cancer of Renal Pelvis
- Interventions
- Low Dose Rate Brachytherapy (LDR), Standard-of-Care Immunotherapy
- Radiation · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- CNS Lymphoma
- Interventions
- Zanubrutinib, Methotrexate, Polatuzumab Vedotin, Rituximab, Cyclophosphamide, Doxorubicin, Prednisone
- Drug
- Lead sponsor
- Juan P. Alderuccio, MD
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 20 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2030
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Rare Diseases
- Interventions
- clinical whole genome sequencing (cWGS)
- Other
- Lead sponsor
- Illumina, Inc.
- Industry
- Eligibility
- 1 Day to 120 Days
- Enrollment
- 355 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2020
- U.S. locations
- 5
- States / cities
- Orange, California • St Louis, Missouri • Omaha, Nebraska + 2 more
- Conditions
- Acute Exacerbation of COPD
- Interventions
- Hemolung Respiratory Assist System, Invasive mechanical ventilation
- Device
- Lead sponsor
- Alung Technologies
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 113 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 32
- States / cities
- Sacramento, California • Denver, Colorado • Newark, Delaware + 28 more
- Conditions
- Tibial Plateau Fracture, Pain, Postoperative
- Interventions
- Duloxetine, Placebo, Standard of care (SOC) for tibial plateau surgery
- Drug · Other
- Lead sponsor
- Boston Medical Center
- Other
- Eligibility
- 18 Years to 80 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 2
- States / cities
- Boston, Massachusetts • Valhalla, New York
- Conditions
- Head and Neck Squamous Cell Carcinoma (HNSCC), Pancreatic Adenocarcinoma, Non-small Cell Lung Cancer (NSCLC), Platinum-resistant High-grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers (HGSOC), Hormone Receptor Positive [HR+] and Human Epidermal Growth Factor Receptor 2 Negative [HER2-] Breast Carcinoma, Triple Negative Breast Cancer (TNBC)
- Interventions
- GTAEXS617, SoC
- Drug
- Lead sponsor
- Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 230 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2028
- U.S. locations
- 6
- States / cities
- Los Angeles, California • Grand Rapids, Michigan • New York, New York + 3 more
- Conditions
- Sickle Cell Disease
- Interventions
- Voxelotor Oral Tablet
- Drug
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 12 Years to 30 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 2
- States / cities
- St Louis, Missouri • The Bronx, New York
- Conditions
- Chronic Myelogenous Leukemia
- Interventions
- Therapy for Targeted Therapy-related Fatigue (TTF), Wait-List Control Condition (WLC)
- Other
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 48 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2021
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Pulmonary Aspergillosis
- Interventions
- Opelconazole, Standard of Care
- Drug
- Lead sponsor
- Pulmocide Ltd
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 102 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • La Jolla, California • Los Angeles, California + 11 more
- Conditions
- Acquired Immunodeficiency Syndrome (AIDS)
- Interventions
- AIDS EPC Package plus MI, Standard of Care (SOC)
- Behavioral · Other
- Lead sponsor
- Emory University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 121 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 1
- States / cities
- Atlanta, Georgia
- Conditions
- Anatomic Total Shoulder Arthroplasty
- Interventions
- Anatomic TSA using IRI Instrumentation, Anatomic Total Shoulder Arthroplasty
- Device · Procedure
- Lead sponsor
- The Cleveland Clinic
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 56 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Corneal Edema, Corneal Defect, Anterior Chamber Inflammation, Ocular Pain, Corneal Staining, Visual Outcome, CME - Cystoid Macular Edema
- Interventions
- Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1% Oph Susp, Prolensa 0.07% Ophthalmic Solution
- Drug
- Lead sponsor
- Nicole Fram M.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2025
- U.S. locations
- 1
- States / cities
- Los Angeles, California